SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) today announced the
retirement of its executive vice president and chief financial officer
(CFO), John Cajigas, effective December 31, 2017. Leigh Vosseller, who
is currently serving at Tandem's senior vice president of finance, will
be promoted to CFO effective January 1, 2018.
"I want to thank John for his many contributions to Tandem over the past
10 years and wish him the best of luck in his future endeavors," said
Kim Blickenstaff, president and chief executive officer of Tandem
Diabetes Care. "Leigh brings a passion for leading teams, delivering
results, and providing financial stewardship and discipline that makes
her ideally suited for this expanded role. With our positive sales
momentum in the fourth quarter, and our anticipation of key business
inflection points in 2018, we expect Leigh will play a pivotal role as
we drive toward sustained profitable growth."
Ms. Vosseller joined Tandem in September 2013 as vice president of
finance. Prior to that time, she served as vice president and CFO at
Genoptix, Inc. (a Novartis company) beginning in 2011, after initially
joining the company in 2008. Prior to that she held a senior finance
position at Biosite Incorporated where she played a key role in
developing the financial and administrative infrastructure for
international expansion. Ms. Vosseller is a certified public accountant
(inactive) and holds a bachelor's degree in accounting from Missouri
Mr. Cajigas' retirement is not related to any disagreement with, or
inaccuracy or omission in, the Company's accounting systems or financial
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, and the t:flex® Insulin Pump, the first pump
designed for people with greater insulin requirements. Tandem is based
in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2,
#tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care on
Facebook at www.facebook.com/TandemDiabetes.
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Tandem Diabetes Care and t:flex are registered trademarks, and t:slim X2
and t:simulator are trademarks of Tandem Diabetes Care, Inc. Dexcom and
Dexcom G5 are registered trademarks of Dexcom, Inc. All other trademarks
are the property of their respective owners.
Forward Looking Statement
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the Company's sales momentum and future
profitability. The Company's actual results may differ materially from
those indicated in these forward-looking statements due to numerous
risks and uncertainties. For instance, the Company's ability to achieve
future profitability will be impacted by market acceptance of the
Company's new products and products under development by healthcare
providers, third-party payors and people with diabetes; the potential
that negative perceptions regarding the Company's financial stability
relative to that of its competitors, and its ability to sustain business
operations on a long-term basis, may cause consumers to delay the
purchase of its products or to purchase competitive products; the
Company's ability to receive required regulatory approvals and otherwise
complete the transition of manufacturing operations to its new
manufacturing facility when anticipated; and the potential that newer
products that compete with the Company's products, or other
technological breakthroughs for the monitoring, treatment or prevention
of diabetes, may render its products obsolete or less desirable. Other
risks and uncertainties are identified in the Company's most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other
documents that the Company files with the Securities and Exchange
Commission. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Tandem undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171207006143/en/
Tandem Diabetes Care, Inc.
Susan Morrison, 858-366-6900 x7005
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media